Novel functionalization of liposomic nano-vehicles for strongly-enhanced drug de...
Novel functionalization of liposomic nano-vehicles for strongly-enhanced drug delivery
Delivery to diseased cells or tissues of therapeutic agents attached or encapsulated in nanoparticles – nanomedicine - presents many benefits, and comprises a rapidly-growing multi-billion-euro market. Lipid-based drug-delivery na...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
OatLive
Mix and Match: One-step activation for targeted drug deliver...
150K€
Cerrado
FluoNeeD
Fluorinated Lipid Nanoparticles for Gene Delivery and Diagno...
212K€
Cerrado
BiofilmEradicate
Modification of liposomic nano-carriers: a novel strategy fo...
150K€
Cerrado
SAF2010-15547
NANOSISTEMAS PARA LA ADMINISTRACION ORAL DE AGENTES ANTITUMO...
145K€
Cerrado
RTI2018-101309-B-C21
SINTESIS Y CARACTERIZACION DE NANOGHOSTS COMO SISTEMAS NOVED...
154K€
Cerrado
PID2021-122187NB-C31
FORMULACION DE NUEVOS NANOPORTADORES NO LIPIDICOS CRISTALINO...
145K€
Cerrado
Información proyecto NanoDeliveryEnhance
Duración del proyecto: 18 meses
Fecha Inicio: 2023-01-26
Fecha Fin: 2024-07-31
Descripción del proyecto
Delivery to diseased cells or tissues of therapeutic agents attached or encapsulated in nanoparticles – nanomedicine - presents many benefits, and comprises a rapidly-growing multi-billion-euro market. Lipid-based drug-delivery nano-vehicles, where drugs (not least the recent, very-widely-used, mRNA-based COVID-19 vaccines) are encapsulated in lipid vesicles (liposomes) or lipid nanoparticles, form a substantial part of that market. Nearly all FDA-approved liposomic vehicles are functionalized with poly(ethylene glycol), PEG, moieties, the current gold-standard. These act both to sterically-stabilize the vesicles, and, importantly, increase their blood-retention time and thus their therapeutic efficiency. At the same time, such PEGylation has several drawbacks, including reduced cellular uptake, accumulation of PEG in tissues, and accelerated blood clearance on repeated intravenous dosage due to heightened immune response. We use novel functionalization approaches to overcome these drawbacks. The present project explores the innovation dimension of our new approach. In particular, is it effective? is it efficient? How widely applicable is it? What is the IPR position for future exploitation of this new strategy? These questions illustrate the high-risk/high-gain nature of this proposal, and are addressed here through several inter-related work packages. Success of our project in demonstrating that our novel approach is significantly superior to the current universally-used PEGylation would not only have a therapeutic advantage for many diseases, but also tap into a large and growing market.